Overcoming the barriers of osteoporosis treatment—A better route and a longer use  by Lee, Wen-Ling et al.
Available online at www.sciencedirect.comScienceDirect
Journal of the Chinese Medical Association 78 (2015) 567e568
www.jcma-online.comEditorialhttp://d
1726-4Overcoming the barriers of osteoporosis treatmentdA better route
and a longer useThe incidence of osteoporosis, defined as decreased bone
mass and altered microarchitecture of the bone, has inevitably
increased in postmenopausal women.1,2 The subsequent mor-
bidity arising from osteoporosis, which includes vertebral and/
or hip fractures, can lead to debilitating health outcomes and a
considerable economic burden on the health care system.3,4
Therefore, recent attention, which includes the author's study
in this issue, has focused on the use of various kinds of drugs
to manage osteoporosis in postmenopausal women.5
There are several agents (i.e., antiosteoporosis drugs)
available for treating osteoporosis such as conventional
estrogen-based hormone therapy, bisphosphonates (e.g.,
alendronate, ibandronate, risedronate, zoledronic acid), cal-
cite, selective estrogen receptor modulators (e.g., raloxifene),
parathyroid hormone (e.g., teriparatide), and RANK ligand
inhibitors (e.g., denosumab). All of these medications have
demonstrated their efficacy in the prevention of osteoporosis
and osteoporosis-related fracturesdespecially vertebral frac-
turesdin postmenopausal women.6,7 However, osteoporosis
remains a challenging disease to treat because of several
barriers such as occasional irregular patient adherence to
therapies. The decision to use an antiosteoporosis drug should
be tailored to the patient's specific clinical scenario.8 The
extent of compliance with osteoporosis pharmacological
treatment, as measured by the medication possession ratio, is
reportedly poor in clinical practice. Poor compliance is defined
as a medication possession ratio less than the threshold of
0.80.9 Noncompliance can arise from several different causes,
which include an overlooked risk of osteoporosis and
osteoporosis-related morbidity and mortality, an inconvenient
use of an antiosteoporosis agent (e.g., teriparatide), adverse
effects of an agent such as gastrointestinal upset after
administration of the oral form of bisphosphonate, exacer-
bating climacteric symptoms after raloxifene use, and anxiety
concerning unwanted adverse effects such as increased breast
cancer risk with conventional estrogen-based hormone
therapy.
Bisphosphonates are first-line agents in the treatment of
osteoporosis and are efficacious in substantially reducing the
fracture risk between 25% and 70%, on average, depending
on the fracture site.3 They also are the same agent as oral
minodronate that is referenced in the authors' study published
in the current issue.5 However, patient compliance with oralx.doi.org/10.1016/j.jcma.2015.07.002
901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assbisphosphonate pills can be poor and significantly deter the
proper management of osteoporosis. It is quite fortunate that
the adverse effects of the current medication (i.e., oral
minodronate) such as gastrointestinal upset or other
uncomfortable potential consequences did not occur in this
study.5 We firmly believe that this antiosteoporosis agent
may be more acceptable in the future, and result in higher
patient compliance with osteoporosis medications. The
authors unfortunately did not report the compliance of the
study population in the current issue.5 This element is
important because reportedly only 34e55% of patients are
compliant with approved osteoporosis treatment, and a sig-
nificant decline in patient adherence to pharmacological
recommendations in subsequent years is also apparent.9 In
addition, an inverse relationship between compliance and
risk of fracture is well established. A progressive reduction in
fracture risk starts at a medication possession ratio of 0.50.
The greatest risk reduction was achieved at a medication
possession ratio greater than 0.75 in a study of patients with
osteoporosis who received the oral form of bisphosphonate
therapy.10 The overall risk of vertebral, hip or either one of
both fractures was 20%, 46%, and 51% higher, respectively,
in noncompliant patients with osteoporosis who were treated
by bisphosphonate (odds ratio, 1.20, 1.46, and 1.51, respec-
tively; 95% confidence interval, 1.07e1.35, 1.16e1.82, and
1.10e2.06, respectively).10 By contrast, there is a 37% risk
reduction in hip or vertebral fractures in compliant patients
who received the same treatment of bisphosphonate.10 The
risk of hip fracture increased by 0.4% for every 1% decline
in medication possession ratio,9 which suggests that a better
route and a longer use of antiosteoporosis agents may pro-
vide a maximally therapeutic effect for patients with osteo-
porosis. Therefore, a clinical trial needs to consider the
compliance of patients to evaluate successfully the efficacy
of an antiosteoporosis treatment. More compliant patients are
more likely to have a reduced risk of fracture. Every effort
should be made to participate in detailed conversations
between patients and physicians and to provide a compre-
hensive explanation to patients because successful outcomes
are associated with adherence and/or compliance.11 In
addition, adherence- and/or compliance-related outcomes are
associated with beliefs about these antiosteoporosis agents,
especially oral treatment with bisphosphonates.ociation. All rights reserved.
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